Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease
Arjun Pandey(University of Toronto), Subodh Verma(University of Toronto), Nikolaus Marx(University of Cologne), Javed Butler(University of Mississippi Medical Center), Bertram Pitt(Bayer (Germany)), Francesco Cosentino(University of Zurich), Ori D. Rotstein(St. Michael's Hospital), Ambarish Pandey(The University of Texas Southwestern Medical Center), Deepak L. Bhatt(Brigham and Women's Hospital)
Cited by 71
Related Papers
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k